|
1
|
Dear K, Psomadakis C, Dost S, Lalagianni N, Oldham J, Hew A, Kenny J, Riphagen S, Greenblatt D, Flohr C, Abdelrahman W. Cutaneous manifestations of PIMS-TS: a single centre experience. Br J Dermatol 2021; 186:902-903. [PMID: 34842283 DOI: 10.1111/bjd.20907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 11/18/2021] [Accepted: 11/21/2021] [Indexed: 11/29/2022]
Abstract
Paediatric inflammatory multisystem syndrome associated with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection (PIMS-TS) is defined as 'a child presenting with persistent fever, inflammation and evidence of single or multi-organ dysfunction with additional features which include a rash'.1 The World Health Organisation's (WHO) definition further includes a 'rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs'.2 Previously reported mucocutaneous manifestations (MCM) in PIMS-TS have been vague. This study aimed to delineate the MCM of children presenting with PIMS-TS in more detail.
Collapse
Affiliation(s)
- K Dear
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| | - C Psomadakis
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| | - S Dost
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| | - N Lalagianni
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| | - J Oldham
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| | - A Hew
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| | - J Kenny
- Evelina London Children's Hospital, Department of Paediatric Infectious Diseases London, London, United Kingdom of Great Britain and Northern Ireland
| | - S Riphagen
- Evelina London Children's Hospital, Department of Paediatric Infectious Diseases London, London, United Kingdom of Great Britain and Northern Ireland
| | - D Greenblatt
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| | - C Flohr
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| | - W Abdelrahman
- Guy's and St Thomas' Hospitals NHS Trust, St John's Institute of Dermatology, London, London, United Kingdom of Great Britain and Northern Ireland
| |
Collapse
|
|
2
|
Psomadakis C, Kallerghi G, Bourantas C, Papageorgiou J. Experience with isoxsuprine in the treatment of sickle cell crisis: a proposed mechanism of action. Angiology 1981; 32:249-56. [PMID: 7224235 DOI: 10.1177/000331978103200405] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
An accidental clinical observation triggered this investigation into the possible beneficial effects of isoxsuprine in the treatment of painful sickle cell crisis. Twenty-four patients were studied with a total of 34 episodes of painful crisis. As they had all been previously treated by us we knew the duration of their crisis under conventional treatment, so that the two regimens with and without isoxsuprine could be compared. Isoxsuprine was administered in 3 successive steps: (1) as an IM injection (5-10 mg), (2) as a rapid IV infusion (1 mg/minute), and (3) as a slow, continuous IV infusion, (0.1-0.3 mg/minute). The results from this study suggest that isoxsuprine exerts in fact a remarkable action in sickle cell crisis by bringing about prompt relief in approximately 80% of the cases within 5 hours, and in 40% of the cases within 2 hours. There were only 2 cases of absolute failure. The hospitalization time was remarkably reduced and the use of narcotics was minimized. Side effects (tachycardia, palpitations, somnolence) have been observed mainly in cases where relatively high doses of isoxsuprine had to be administered IV.
Collapse
|
|
3
|
Lolis D, Creatsas G, Psomadakis C, Kaskarelis D. Leucocyte alkaline phosphatase activity during high risk pregnancies. Br J Haematol 1978; 39:277-81. [PMID: 678479 DOI: 10.1111/j.1365-2141.1978.tb01098.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
142 determinations of leucocyte alkaline phosphatase (LAP) activity have been done in 103 cases of high risk pregnancy. A statistically significant elevation of LAP score has been found in high risk pregnancies due to diabetes mellitus, toxaemia, renal diseases and third trimester haemorrhage, but not in pregnancies complicated by cardiac disease, chronic hypertension, Rh sensitization or anaemia.
Collapse
|
|
4
|
Costantinidis A, Psomadakis C, Maurikakis M, Papageorgiou C. [Porphyria with neuropsychiatric manifestations and contraceptive agents]. Minerva Ginecol 1973; 25:192-5. [PMID: 4710129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|